Conflicts of Interest
depression, HAMD, anxiety
ADVERSE REACTIONS
The authors declare that they have no conflicts of interest.Uterine volume and endometrial thickness in the two groups before and after therapy. (a) Uterine volume in the study and control groups before and after therapy. (b) Endometrial thickness in the study and control groups before and after therapy.LH, FSH, E2, and melatonin level before and after treatment in the two groups. LH: luteinizing hormone, FSH: follicle generating hormone, and E2: estradiol. (a) LH level in the study and control groups before and after therapy. (b) FSH level in the study and control groups before and after therapy. (c) E2 level in the study and control groups before and after therapy. (d) Melatonin level in the study and control groups before and after therapy. Kupperman and MENQOLscores in the two groups before and after therapy. MENQOL: the menopausal quality of life (a). Kupperman scores in the study and control groups before and after therapy. (b). MENQOL scores in the study and control groups before and after therapy. HAMD, HAMA, and PSQI scores in the two groups before and after treatment. HAMD: the Hamilton depression scale, HAMA: the Hamilton anxiety scale, and PSQI: the Pittsburgh sleep quality index. (a) HAMD scores in the study and control groups before and after therapy. (b) HAMA scores in the study and control groups before and after therapy. (c) PSQI scores in the study and control groups before and after therapy. Demographic characteristics of included participants.Uterine volume and endometrial thickness in the two groups before and after treatment.
LH, FSH, E2, and melatonin levels before and after treatment in the two groups.LH: luteinizing hormone, FSH: follicle generating hormone, E2: estradiol Kupperman and MENQOL scores in the two groups before and after treatment.
HAMD, HAMA, and PSQI scores in the two groups before and after therapy.
Adverse reactions before and after treatment in the two groups.
